All articles tagged with #ldl
Eli Lilly’s high-dose, one-time gene-editing therapy VERVE-102 lowered LDL cholesterol by 62% in a Phase 1 trial, with no treatment-related serious adverse events, signaling potential for a single-shot approach to prevent heart disease after Lilly’s $1 billion acquisition of Verve Therapeutics.
Remnant cholesterol, carried by large lipoprotein particles and rich in triglycerides, may drive heart disease more than LDL; it’s rarely measured, and while statins mostly lower LDL, newer drugs plus diet and weight loss can significantly reduce remnant cholesterol and cardiovascular risk.
Researchers screened thousands of compounds in lab-grown human liver cells and identified DL-1, a triazine thiol, that lowers apoB and reduces total cholesterol without causing fatty liver; in mice with humanized livers, a soluble DL-27 version lowered cholesterol metrics, suggesting a safer alternative for severe inherited high cholesterol (familial hypercholesterolemia) beyond current statins.
Experts say the best cholesterol improvements come from a blend of aerobic cardio and resistance (weight) training. Cardio lowers LDL, vLDL and triglycerides while raising HDL function; resistance training also raises HDL about as much as cardio and can improve LDL, vLDL and triglycerides with consistent effort. For meaningful change, aim to burn about 1,000–1,200 calories per week (roughly five 50‑minute cardio sessions) and train 2–3 times weekly for resistance. If you stay consistent, you may see lipid improvements in 4–8 weeks; combining exercise with diet changes yields the biggest LDL reductions (20–30%).
Doctors lowered the LDL cholesterol targets and tied them to an individual’s overall cardiovascular risk, enabling earlier, risk-driven prevention. The guidance uses the PREVENT calculator to decide when lifestyle changes suffice versus when medications should begin, with statins remaining first-line and quicker escalation to ezetimibe or injections if needed. The update also recommends testing lipoprotein(a) and apolipoprotein B, considers targeted imaging in uncertain cases, and calls for earlier screening (adults at 19; kids around 9–11) to detect inherited hypercholesterolemia and start prevention before emergencies.
Regular aerobic exercise, at least 120 minutes per week (about 20 minutes daily), can modestly lower LDL by 3–6 mg/dL and improve triglycerides and HDL; a combination of cardio and strength training yields the strongest cholesterol-related benefits and broader heart-health gains.
High LDL cholesterol raises heart attack and stroke risk, but being lean doesn’t guarantee safety; genetics and saturated-fat intake largely drive LDL levels. Obesity mainly affects other lipids (triglycerides and remnant cholesterol) and is linked to diabetes and high blood pressure, which can make LDL more harmful. Overall cardiovascular risk isn’t determined by LDL alone, so a clinician should assess it—consider NHS checks from age 40 and family history of early heart disease.
Researchers at the Medical University of South Carolina are pursuing a treatment for familial hypercholesterolemia by reducing apoB, the backbone of LDL particles, using human iPSC-derived liver cells to screen about 130,000 compounds. A lead class lowered apoB release and cellular lipid levels in human cells and in humanized mice, bypassing the LDL receptor and potentially helping patients with defective receptors. Further work will clarify the mechanism, safety, and how such drugs could complement existing therapies like statins.
Cardiologists say the only reliable way to know if cholesterol is too high is a blood test. High LDL and low HDL increase heart-disease risk, and new guidelines call for regular lipid screening—from childhood through adulthood (every five years) and measuring lipoprotein(a) at least once. Most people have no early symptoms, so routine testing plus healthy lifestyle choices (diet, exercise, no smoking) are key; signs like chest pain or shortness of breath usually appear only after disease has progressed.
A comprehensive look at common statin myths: large randomized trials show muscle pain is largely a nocebo effect, with true statin-related pain being rare; any diabetes risk from statins is small in absolute terms (low-dose increases ~0.12% per year, high-dose ~1.27% per year) and outweighed by big reductions in heart attacks and strokes; memory loss and liver damage are not proven causal effects and serious liver injury is extremely rare; and the greatest benefit comes from combining statins with healthy lifestyle changes. High-dose statins can lower LDL by about 50% and, when paired with lifestyle improvements, significantly reduce cardiovascular risk.
The 2026 ACC/AHA dyslipidemia guidelines call for earlier, more personalized cholesterol screening (even in children for familial hypercholesterolemia), broader risk assessment including genetic factors like Lp(a), and introduce a new PREVENT calculator to estimate 10- and 30-year cardiovascular risk, with expanded treatment options and lower LDL targets to prevent heart disease decades down the line.
The 2026 cholesterol guidelines from the ACC and AHA expand risk assessment to ages 30–79, emphasize lifetime risk, restore explicit LDL targets (<100 mg/dL for low risk, <70 mg/dL for higher risk, <55 mg/dL for very high risk), add one-time Lp(a) testing to uncover genetic risk, and encourage earlier lifestyle changes and targeted therapies to prevent heart disease.
A phase 3 trial of the daily oral PCSK9 inhibitor enlicitide showed LDL cholesterol falls by about 60% in 2,909 patients with atherosclerosis or high cardiovascular risk, many already on statins. The pill also reduced non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), with effects lasting one year. If FDA approves, enlicitide could offer an oral alternative to injectable PCSK9 therapies and improve adherence, though a separate study is needed to confirm whether these LDL reductions translate into fewer heart attacks and strokes. The trial was Merck-funded and ongoing work aims to determine cardiovascular event outcomes.
New cholesterol guidelines urge starting screening in your 30s and using lifetime risk (via the PREVENT calculator) alongside 10-year risk to guide treatment. Targets are LDL <100 mg/dL for most, <70 mg/dL for high-risk individuals, and <55 mg/dL for those with existing heart disease, with statins considered earlier; the guidance also recommends apoB testing after LDL goals and universal lipoprotein(a) testing once in adulthood, plus calcium scoring for those at borderline/intermediate risk, all aiming to reduce lifetime LDL exposure and prevent cardiovascular events.
New cardiovascular guidelines urge starting lipid management as early as age 30, using the PREVENT risk calculator and lower LDL targets (under 100 mg/dL for lower-risk, under 70 mg/dL for high risk, and under 55 mg/dL for very high risk). They endorse lifestyle changes, consider coronary calcium scans and biomarkers like Lp(a) and ApoB to guide therapy, and include statins and, in some cases, PCSK9 inhibitors as part of a broader prevention strategy.